Worth reading
52Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
5.1
Year-on-year revenue growth (%)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPNet Sales842,512¥ millionYear on year +5.1%Progress 96.2%
Operating profit46,831¥ millionYear on year +5.2%Progress 96.0%
Ordinary income46,220¥ millionYear on year +5.4%Progress 96.1%
Net income attributable to owners of the parent31,392¥ millionYear on year +2.1%Progress 97.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥268.36
Operating Margin5.6%
Financial position at period-end
Total assets475,505¥ million
of which net assets 286,001 ¥ millionEquity ratio 60.1%vs. prior year-end -0.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+43,297
Investment-32,076
Financials-5,653
Net change+5,568
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥70,523 million
Segment revenue
Drugstore Business539,37959.7%+4.3%
Discount store business364,12140.3%+6.4%
Segment profit
Drugstore Business27,48158.7%+3.1%
Discount store business19,35041.3%+8.4%
Regional salesNo sales to external customers outside Japan (amount for Japan not disclosed)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥876,000 million (YoY +4.0%)
Operating profit¥48,800 million (YoY +4.2%)
Ordinary income¥48,100 million (YoY +4.1%)
Net income¥32,150 million (YoY +2.4%)
Annual Dividend Forecast¥130 per share → ¥132 per share
Payout ratio48.0%
Factors Behind Changes in Business Performance
Higher revenue and higher profits resulted from new store openings, renovations of existing stores, strong performance in the pharmacy and e-commerce businesses, strong sales of rice held in reserve and food products, improved transaction terms, and productivity improvements. Declining sales of certain seasonal products, including cold remedies and seasonal home appliances, were negative factors.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 Yes修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsNot applicable.
Impairment loss¥399 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥84 million / Penalty income ¥17 million / Government subsidies ¥475 million / Other ¥26 million / Total ¥604 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥228 million / Loss on cancellation of lease agreements ¥5 million / Impairment loss ¥399 million / Loss on reduction of fixed assets ¥273 million / Losses from natural disasters ¥4 million / Other ¥109 million / Total ¥1,021 million
Depreciation and amortization¥18,760 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End119,331,184 shares
Treasury Shares at Period-End2,348,285 treasury shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥842,512 million (YoY +5.1%) |
| Operating profit | ¥46,831 million (YoY +5.2%) |
| Ordinary income | ¥46,220 million (YoY +5.4%) |
| Profit attributable to owners of the parent | ¥31,392 million (YoY +2.1%) |
| Net income per share | ¥268.36 |
| Operating Margin | 5.6% |
| Equity ratio | End of the current fiscal period 60.1% / End of previous period 60.7% |
| Total assets | ¥475,505 million |
| Net assets | ¥286,001 million |
| Cash flows from operating activities | ¥43,297 million |
| Cash flows from investing activities | ¥-32,076 million |
| Cash flows from financing activities | ¥-5,653 million |
| Cash and cash equivalents at end of period | ¥70,523 million |
| Full-year earnings forecast | Net Sales ¥876,000 million (YoY +4.0%) / Operating profit ¥48,800 million (YoY +4.2%) / Ordinary income ¥48,100 million (YoY +4.1%) / Net income ¥32,150 million (YoY +2.4%) |
| Annual Dividend Forecast | ¥130 per share → ¥132 per share |
| Payout ratio | 48.0% |
| Segment revenue | Segment Drugstore Business / Net Sales ¥539,379 million / Year on year against the same period last year Up 4.3%, Segment Discount store business / Net Sales ¥364,121 million / Year on year against the same period last year Up 6.4% year on year |
| Segment profit | Segment Drugstore Business / Segment profit ¥27,481 million / Year on year against the same period last year Up 3.1% year on year, Segment Discount store business / Segment profit ¥19,350 million / Year on year against the same period last year Up 8.4% year on year |
| Regional sales | No sales to external customers outside Japan (amount for Japan not disclosed) |
| Depreciation and amortization | ¥18,760 million |
| Impairment loss | ¥399 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥84 million / Penalty income ¥17 million / Government subsidies ¥475 million / Other ¥26 million / Total ¥604 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥228 million / Loss on cancellation of lease agreements ¥5 million / Impairment loss ¥399 million / Loss on reduction of fixed assets ¥273 million / Losses from natural disasters ¥4 million / Other ¥109 million / Total ¥1,021 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 119,331,184 shares |
| Treasury Shares at Period-End | 2,348,285 treasury shares |
| Factors Behind Changes in Business Performance | Higher revenue and higher profits resulted from new store openings, renovations of existing stores, strong performance in the pharmacy and e-commerce businesses, strong sales of rice held in reserve and food products, improved transaction terms, and productivity improvements. Declining sales of certain seasonal products, including cold remedies and seasonal home appliances, were negative factors. |
Items this document does not state (3)
Revision to Earnings ForecastShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Contributions came from opening new stores, renovating existing stores, strong performance in the pharmacy and e-commerce businesses, strong sales of rice held in reserve and food products, improved transaction terms, and initiatives to improve productivity. On the other hand, sales of certain seasonal products, including cold remedies and seasonal home appliances, declined.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.